BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302545% above fair value
$411.29−5.25 (-1.26%)
Close on Nov 16, 2026Market cap $46.76BP/E 73.6Yield –
BeOne Medicines price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
BeOne Medicines's price to sales ratio was 7.7× on Nov 11, 2026, against 7.6× a year earlier. Over the last 5 years it ranged from 5.4× to 23.8×, with a median of 7.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 7.7× | +1.0 |
| 2025 | Dec 31, 2025 | 6.8× | +0.8 |
| 2024 | Dec 31, 2024 | 5.9× | −2.6 |
| 2023 | Dec 29, 2023 | 8.5× | −9.8 |
| 2022 | Dec 30, 2022 | 18.3× | −5.5 |
| 2021 | Dec 31, 2021 | 23.8× | −64.7 |
| 2020 | Dec 31, 2020 | 88.5× | +86.2 |
| 2019 | Dec 31, 2019 | 2.3× | −50.4 |
| 2018 | Dec 31, 2018 | 52.7× | +32.6 |
| 2017 | Dec 29, 2017 | 20.1× | −154.0 |
| 2016 | Dec 30, 2016 | 174.1× | – |
See a number that looks wrong?